Trial reportGastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association2026
A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 followed by gastrectomy for type 4 or large type 3 gastric cancer (OGSG 1402).
Trial report in Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
23 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundA multi-institutional phase II study (OGSG 1402) evaluated the efficacy and safety of neoadjuvant docetaxel, cisplatin, and S-1 (DCS) therapy for type 4 or large type 3 gastric cancers.
methodsPatients with macroscopic type 4 or large type 3 gastric cancer received two or three cycles of neoadjuvant DCS therapy (docetaxel 40 mg/m
resultsBetween March 2015 and June 2018, 48 patients were enrolled, 47 of whom were eligible. The R0 resection rate was 68.1% (32/47, 95% confidence interval [CI] 52.9-80.9). Forty-two patients (89.4%) completed neoadjuvant chemotherapy (NAC). The most common grade 3 or 4 adverse event during NAC was neutropenia (23/47, 48.9%). Surgical morbidity of Clavien-Dindo grade IIIa or higher occurred in 8.5% (4/47) of patients. The pathological response rate, defined as grades 1b to 3, was 42.6% (20/47, 95% CI 28.3-57.8). The 5-year overall survival rate was 38.3% (95% CI 24.6-51.8) and the 5-year progression-free survival rate was 29.8% (95% CI 17.6-43.0).
conclusionsIn patients with type 4 or large type 3 gastric cancer, neoadjuvant DCS therapy did not meet the predefined threshold for the R0 resection rate. Despite its acceptable feasibility and manageable toxicity, the addition of docetaxel to the S-1 plus cisplatin regimen is unlikely to provide a survival benefit for this high-risk population.
trial registrationThe study was registered with UMIN-CTR (number UMIN 000015631).
Indexed as
Identifiers
41843003What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.